WuXi Biologics signs lease for a clinical manufacturing site in Cranbury

WuXi Biologics, a global company with leading open-access biologics technology platforms, announced on Tuesday it has signed a 10-year lease for a clinical manufacturing site in Cranbury.

The 66,000-square-foot facility will install bioreactors, process development, quality control labs and support functions. It is slated to open in late 2020 and will bring 100 jobs to the region.

“We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide,” Dr. Chris Chen, CEO of WuXi Biologics, said.

The company said it recently purchased a 107,000-square-foot manufacturing facility in Worcester, Massachusetts, and leased a 33,000-square-foot process development lab in King of Prussia, Pennsylvania.